University of Strathclyde Background
Mironid Limited is an innovative drug discovery company that develops proprietary drug candidate molecules by modulating the activity of key cell signalling proteins. This allows access to multiple therapeutic areas for exploitation. Current drug discovery pipeline is aimed at developing novel treatments for degenerative kidney diseases, chronic inflammatory diseases and cancer.
Mironid’s unique Physiology Mirroring approach uses deep biological knowledge of cell signalling to design assays that mirror the drug target’s conformation and environment found in living cells. This allows the team to dial-up and down the activity of key cell signalling enzymes to rebalance aberrant signals that drive different disease states.
Potential uses for Mironid’s technology are in the pharmaceutical industry.